Order TriFECTa™ Library & Kit
Order TriFECTa™ ReadyMade Control Duplexes
Download TriFECTa™ RNAi Kits Quick Start Guide
Download TriFECTa™ User's Manual


The TriFECTa™ kit contains three Screening Dicer-substrate (DsiRNA) duplexes targeting a specific gene that are selected from a predesigned collection of duplexes in the DsiRNA RefSeq Library. The DsiRNAs target sites were chosen by a rational design algorithm that integrates both traditional 21-mer siRNA design rules as well as new Dicer-substrate design criteria.

In addition to three target-specific duplexes, the TriFECTa™ kit contains three control sequences that are needed to perform RNAi experiments, including a TYE 563™-labeled transfection control RNA Duplex, a scrambled universal negative control RNA duplex, which is absent in human, mouse, and rat genomes and a positive control DsiRNA duplex, which targets a site in the HPRT (hypoxanthine guanine phosphoribosyltransferase gene that is common between human, mouse, and rat and is prevalidated to give >90% knockdown of HPRT when transfected at 10 nM concentration.

IDT guarantees that at least two of the three Screening DsiRNA duplexes in the TriFECTa™ kit will give at least 70% knockdown of the target mRNA when used at 10 nM concentration and assayed by quantitative RT-PCR when the fluorescent transfection control duplex indicates that >90% of the cells have been transfected and the HPRT positive control works with the expected efficiency.

  • Three target-specific Dicer-Substrate siRNA duplexes (2 nmoles each)
  • Fluorescent-labeled transfection control duplex: TYE 563™ (1 nmole)
  • HPRT-S1 DS Positive Control duplex (1 nmole)
  • DS Scrambled-Neg, universal negative control duplex (1 nmole)
  • RNase Free Duplex Buffer (100mM KAc/30 mM HEPES pH 7.5)

The complete TriFECTa™ Kit is $300.00 EUR


THESE PRODUCTS ARE NOT FOR USE IN HUMANS OR NON-HUMAN ANIMALS AND MAY NOT BE USED FOR HUMAN OR VETERINARY DIAGNOSTIC, PROPHYLACTIC OR THERAPEUTIC PURPOSES.


References

1. Synthetic dsRNA Dicer-substrates enhance RNAi potency and efficacy. Kim, D.H., et al., Nat Biotechnol, 23(2): p. 222-6 (2005).

2. Functional polarity is introduced by Dicer processing of short substrate RNAs. Rose, S.D., et al., Nucleic Acids Res, 33(13): p. 4140-56 (2005).